Sorrento Therapeutics Inc (SRNE)

[dia76ca]

I am a value investor. SORRENTO has a very large portfolio. I estimate that the top 3 products could produce a combined revenue in excess of $35 billion. All 3 are in phase 3 and could receive approval this year.
ABIVERTINIB
2 PD-L1's
OVYDSO oral antiviral

SCILEX has a smaller portfolio. However I estimate the top 3 products could produce a combined revenue in excess of another $35 billion.
GLOPERBA gout market approved
SEMDEXA sciatica phase 3 completed. Fast track.
SP-103 lower back pain phase 2 completed, Fast track.

Both SORRENTO and SCILEX intend to partner for World-wide markets. I expect large upfront, milestone and royalty payments. A lot of news to come in 2023!